MORPHOSYS AG ADS news, videos and press releases
For more news please use our advanced search feature.
MORPHOSYS AG ADS - More news...
MORPHOSYS AG ADS - More news...
- MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value
- MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
- MorphoSys Presents Latest Data from the Phase 2 MANIFEST Study Evaluating the Potential of Pelabresib in the Treatment of Myelofibrosis
- MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- MorphoSys and Incyte Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma
- MorphoSys and Incyte Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma
- MorphoSys's Licensing Partner GSK Shared Preliminary Results From OSCAR Study with Otilimab for the Treatment of Severe Pulmonary COVID-19 Related Disease; Expanding the Study for Patients 70 Years and Older
- MorphoSys Appoints Sung Lee as Chief Financial Officer
- Data Evaluating Tafasitamab with and without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented at ASH 2020
- Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab
- Invitation to MorphoSys' Year-End Results 2019 Conference Call on March 19, 2020
- MorphoSys AG: Ad hoc: Primary Endpoint Met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide Compared to Lenalidomide Alone
- MOR106 Clinical Development in Atopic Dermatitis Stopped for Futility
- Invitation to MorphoSys Q3 2019 Conference Call on October 30, 2019
- MorphoSys Discloses Biomarker to Stratify Patient Population in B-MIND Study of Tafasitamab plus Bendamustine in r/r DLBCL
- MorphoSys Announces Intention to Submit Marketing Authorization Application for Tafasitamab to European Medicines Agency
- MorphoSys Announces that its Licensee Janssen Has Received U.S. FDA Approval for Tremfya(R) One-Press Patient-Controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis
- MorphoSys Announces that According to a Presentation Title at an Upcoming Conference, Guselkumab Demonstrates Superior Long-Term Responses to Secukinumab at Week 48 in the Treatment of Moderate to Severe Psoriasis
- MorphoSys to Present at Upcoming Investor Conferences
- DGAP-News: MorphoSys AG Announces Third Quarter 2018 Results
- MorphoSys to Present Data on Investigational Drugs MOR208 and MOR202 in Various Blood Cancer Indications at ASH 2018 Meeting
- MorphoSys to Present at Upcoming Investor Conferences
- MorphoSys Announces its Licensee Janssen has Initiated a Phase 3 Trial (PROTOSTAR) to Evaluate Guselkumab in Pediatric Psoriasis Patients
- MorphoSys and LEO Pharma Expand Strategic Alliance to Develop Peptide-derived Therapeutics
